 |
Deadline for Abstract Submission |
|
|
General Guidelines |
|
|
Categories for Abstract Submission |
|
|
Published Abstracts |
Abstracts that contain new data not available at the original abstract deadline may be submitted for consideration for presentation during the Oral Abstract Sessions on Monday, Tuesday, and Wednesday, February 9-11, 2004. Only abstracts containing novel, cutting-edge information will be considered. Because of the limited number of slots and the nature of late breakers, very few of the submissions will be accepted for presentation.
DEADLINE FOR ABSTRACT
SUBMISSION
The online submission system will
open on December 18, 2003 at 10 am EST and close on January 6, 2004 at 5:30
pm EST. Late Breaker dispositions will be sent on January 12, 2004.
Late Breaker Abstracts should be submitted via the Internet at
www.retroconference.org (tables
and figures should be submitted as MS Word Attachments via the Web site).
GENERAL GUIDELINES
All submitted abstracts should report
new information not previously published or presented at a national or
international scientific meeting before February 8, 2004.
Abstracts should contain the following four components:
| Background: | a concise statement of the issue under investigation | |
| Methods: | the experimental methods used | |
| Results: | specific findings | |
| Conclusions: | summary of findings that are supported by your results |
Please do not include grant acknowledgements, literature references, or copyright or trademark symbols.
Abstracts are considered official communications to the conference. For those Late Breaker Abstracts that are accepted, submitters agree to attend the meeting and present their abstract as scheduled.
CATEGORIES FOR ABSTRACT
SUBMISSION
For review and scheduling purposes, abstracts
will be divided into categories. It is mandatory that one of the
categories listed below be chosen and entered in the category box in the
on-line submission form.
| A. | Immunology |
| B. | Vaccines - Preclinical |
| C. | Vaccines - Clinical Trials (including Preventive and Therapeutic Vaccines) |
| D. | Virology |
| E. | Primary/Acute Infection |
| F. | Pathogenesis |
| G. | Neuropathogenesis and Neurologic Complications |
| H. | Immune-Based Therapies |
| I. | Antiretroviral Therapy - Preclinical and Nonrandomized Phase I/II Trials |
| J. | Antiretroviral Therapy - Randomized Clinical Trials |
| K. | Antiretroviral Therapy - Observational Studies |
| L. | Clinical Pharmacology |
| M. | HIV Drug Resistance |
| N. | Antiretroviral Therapy - Complications |
| O. | Opportunistic Infections (including AIDS-Related Malignancies and KSHV/HHV-8) |
| P. | Hepatitis Virus Co-Infections (including HBV, HCV) |
| Q. | Epidemiology |
| R. | Prevention Studies (including Microbicides) |
| S. | Pediatric/Maternal-Fetal |
| T. | HIV Infection in Women/Women's Health |
| U. | Diagnostics and Monitoring |
| V. | Clinical Care and Research in Developing Countries |
PUBLISHED ABSTRACTS
Accepted abstracts will be published
in the Program and Abstracts of the 11th Conference on Retroviruses and
Opportunistic Infections which will be distributed to all registrants.
In addition, abstracts will be posted on the Web site (www.retroconference.org)
in February 2004.
